Abivax Announces Positive Pre-NDA Interaction with the FDA for Obefazimod
Abivax SA announced successful and constructive pre-NDA discussions with the FDA regarding its leading drug candidate, obefazimod, aimed at treating moderately to severely active ulcerative colitis. The company confirmed it remains on track to submit its first NDA by the end of 2026, following positive Phase 3 trial results. This milestone enhances…